About Us

About MediSieve

MediSieve spun-out from University College London in 2015 to develop and commercialise magnetic blood filtration. The company has raised a total of £2.1M in equity funding and won grants worth a total of over £2M from the Wellcome Trust, Innovate UK, NIHR i4i and the EU Horizon 2020 SME Instrument. With the ability to specifically and selectively remove disease causing agents from the blood, magnetic blood filtration has the potential to transform the treatment of blood borne diseases. The company’s initial targets include Sepsis, Leukaemia and Malaria. Located in the new Imperial College Translation and Innovation Hub in White City, the company is preparing for first in man trials in 2019.

Latest News

Finalist in MedTech London Awards 2019

Finalist in MedTech London Awards 2019
Created on 17-03-2019

We are delighted to be a finalist in the  Investment  category of this year’s MedTech London Awards...
MediSieve raises awareness ahead of World Malaria Day

MediSieve raises awareness ahead of World Malaria Day
Created on 07-03-2019

Medical technology firm MediSieve Ltd is highlighting its work for World Malaria Day on April 25 ...